Education
About Us
Working with TipRanks
Follow Us
Resverlogix Corp. J (TSE:RVX)
TSX:RVX
RVX Stock Chart & Stats
Day’s Range― - ―
52-Week RangeC$0.04 - C$0.30
Previous CloseN/A
Volume1.00K
Average Volume (3M)288.75K
Market Cap
C$34.16M
Enterprise ValueC$116.40M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.49
Next Earnings
Aug 19, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding284,637,700
10 Day Avg. Volume167,474
30 Day Avg. Volume288,749
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Resverlogix News
RVX FAQ
What was Resverlogix Corp. J’s price range in the past 12 months?
Resverlogix Corp. J lowest stock price was C$0.04 and its highest was C$0.30 in the past 12 months.
What is Resverlogix Corp. J’s market cap?
Resverlogix Corp. J’s market cap is C$34.16M.
When is Resverlogix Corp. J’s upcoming earnings report date?
Resverlogix Corp. J’s upcoming earnings report date is Aug 19, 2025 which is in 5 days.
How were Resverlogix Corp. J’s earnings last quarter?
Currently, no data Available
Is Resverlogix Corp. J overvalued?
According to Wall Street analysts Resverlogix Corp. J’s price is currently Overvalued.
Does Resverlogix Corp. J pay dividends?
Resverlogix Corp. J does not currently pay dividends.
What is Resverlogix Corp. J’s EPS estimate?
Resverlogix Corp. J’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Resverlogix Corp. J have?
Resverlogix Corp. J has 284,637,700 shares outstanding.
What happened to Resverlogix Corp. J’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Resverlogix Corp. J?
Currently, no hedge funds are holding shares in TSE:RVX
Resverlogix Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
100.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
9.78%
Trailing 12-Months
Company Description
Resverlogix Corp. J
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. It is developing apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada. The company is headquartered in Calgary, Canada.
Resverlogix (RVX) Earnings & Revenues
Currently, no data available
Please return soon. This page is being updated.
Technical Analysis
Kane Biotech
―
Britannia Life Sciences Inc
―
Tetra Bio-Pharma
―
BetterLife Pharma
―
BioVaxys Technology
―
Ownership Overview
0.68% Insiders
―
Mutual Funds
― Other Institutional Investors
99.32% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---